Les Laboratoires Servier: PharmaVitae Profile

Introduction

This analysis examines the historical and forecast performance for Servier in the prescription pharmaceutical sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Servier's performance against key rivals in the prescription pharmaceutical sector

*Assess the impact of the invalidation of Coversyl's key formulation patents in July 2007 on Servier's forecast revenue performance

*Consider Servier's growth opportunities over 200814; the launch of Valdoxan, expansion of generics subsidiary Biogaran, and growth in RoW markets


Report Highlights

[Studien Infos ausblenden]

ABOUT DATAMONITOR HEALTHCARE 2
About the PharmaVitae team 2
Chapter 1 About this profile 3
PharmaVitae Explorer database 3
Chapter structure 3
Executive summary 3
Quarterly news update 3
Company introduction 4
Company sales 4
Company financials 4
Key products and competitors 4
Data sourcing 4
Sales data 4
Analyst consensus 4
Chapter 2 Executive summary 5
Key findings 5
Prescription pharmaceutical sales and growth rate performance, 2002-14 6
Servier: PharmaVitae forecasts at a glance 7
Strategic insight 8
Highly focused business model 8
1) Small molecule portfolio... 8
2) ... for cardiovascular indications 9
3) Geographic focus avoids US competition 9
Coversyl generics to impact Servier's ACE inhibitor market share to 2014 9
Servier is prepared for a growing generics market 10
French generics market to expand due to healthcare cost pressures 11
Generic pricing will impact extent of Biogaran's growth 12
SWOT analysis 13
Strengths 13
Weaknesses 14
Opportunities 14
Threats 15
Table of Contents 16
Table of figures 18
Chapter 3 Quarterly news update 19
Product developments 19
Deals and alliances 19
Product deals 19
Technology deals 20
Company announcements 21
Chapter 4 Company introduction 22
Key findings 22
Background 23
Key corporate developments 23
M&A history 24
Limited history of M&A prior to mid-1990s 24
Egis acquisition opens door to RoW markets 24
Current corporate structure 25
Branded pharmaceuticals 25
Generic pharmaceuticals 25
Chapter 5 Company sales 26
Key findings 26
Prescription pharmaceutical sales and growth rate analysis, 2002-14 27
Product analysis 29
Product analysis, 2002-08 30
Product analysis, 2008-14 33
Therapy area analysis 36
Geographic analysis 39
Launch/core/expiry analysis 41
Explanation of launch/core/expiry analysis 41
Launch analysis, 2008-14 42
Core analysis, 2008-14 43
Expiry analysis, 2008-14 45
Generics analysis, 2008-14 46
Launch/core/expiry configuration, 2008-14 47
Molecule type analysis 48
Externalization analysis 50
Chapter 6 Company financials 53
Key findings 53
Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 54
Chapter 7 Key products and competitors 55
Key findings 55
Overview 56
Cardiovascular 57
Preterax/Coversyl Plus 57
Overview 57
Sales forecast 58
ACE inhibitor combination proves a lucrative strategy 58
Direct Preterax generics not expected during 2008-14 58
Coversyl 60
Overview 60
Sales forecast 61
Coversyl a key contender in the ACE inhibitor class 61
Generic competition is underway 61
Emerging ARB class to prove key competitors 62
Vastarel 63
Overview 63
Sales forecast 64
What is Vastarel? 64
Twice-daily formulation has dampened the impact of generics 64
Daflon 65
Overview 65
Sales forecast 66
What is Daflon? 66
Pricing and reimbursement changes will impact revenues 66
Natrilix 67
Overview 67
Sales forecast 68
What is Natrilix? 68
Generic competition across the diuretics class 68
Procoralan 69
Overview 69
Sales forecast 70
What is Procoralan? 70
Potential for upside following heart disease clinical data in 2008 70
Endocrine, metabolic and genetic disorders 72
Diamicron 72
Overview 72
Sales forecast 73
Diamicron: an oral antidiabetic 73
Servier's improved formulation has limited sales erosion from generics 73
Decline of the sulfonylureas is less rapid than expected 73
Competition from newer classes of OADs 74
Musculoskeletal 75
Protelos 75
Overview 75
Sales forecast 76
What is Protelos? 76
Competition from branded bisphosphonates and generic alternatives 76
Safety concerns may affect ongoing growth 77
Central Nervous System 78
Valdoxan 78
Overview 78
Sales forecast 79
The first melatonergic antidepressant 79
Failed European submission delays launch 79
Existing marketing experience from Stablon 80
Chapter 8 Appendix 81
R&D pipeline 81
References 81
Abbreviations 82
Exchange rates 83
About Datamonitor 84
About Datamonitor Healthcare 84
Datamonitor consulting 84
Disclaimer 86
List of Tables
Table 1: Servier - PharmaVitae forecasts at a glance 7
Table 2: Servier key product developments, 2009 19
Table 3: Servier product deals and alliances, 2009 19
Table 4: Servier technology deals and alliances, 2009 20
Table 5: Servier company announcements, 2009 21
Table 6: Servier product portfolio overview ($m), 2002-08 30
Table 7: Servier product portfolio overview ($m), 2008-14 33
Table 8: Servier prescription pharmaceutical sales by therapy area ($m), 2008-14 37
Table 9: Servier prescription pharmaceutical sales by geographic region ($m), 2008-14 40
Table 10: Servier launch portfolio overview ($m), 2008-14 42
Table 11: Servier core portfolio overview ($m), 2008-14 43
Table 12: Servier expiry portfolio overview ($m), 2008-14 45
Table 13: Servier generics portfolio overview ($m), 2008-14 46
Table 14: Servier prescription pharmaceutical sales by molecule type ($m), 2008-14 49
Table 15: Servier prescription pharmaceutical sales by source ($m), 2008-14 51
Table 16: Total Servier sales by business unit ($m), 2002-08 54
Table 17: Key products overview 56
Table 18: Preterax: overview 57
Table 19: Preterax: sales forecast ($m), 2008-14 58
Table 20: Coversyl: overview 60
Table 21: Coversyl: sales forecast ($m), 2008-14 61
Table 22: Vastarel: overview 63
Table 23: Vastarel: sales forecast ($m), 2008-14 64
Table 24: Daflon: overview 65
Table 25: Daflon: sales forecast ($m), 2008-14e 66
Table 26: Natrilix: overview 67
Table 27: Natrilix: sales forecast ($m), 2008-14 68
Table 28: Procoralan: overview 69
Table 29: Procoralan: sales forecast ($m), 2008-14 70
Table 30: Diamicron: overview 72
Table 31: Diamicron: sales forecast ($m), 2008-14 73
Table 32: Protelos: overview 75
Table 33: Protelos: sales forecast ($m), 2008-14 76
Table 34: Valdoxan: overview 78
Table 35: Valdoxan: sales forecast ($m), 2008-14 79
Table 36: Servier's R&D pipeline (Phase I-registration) 81
Table 37: Exchange rates, 2009 83
List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Servier focus strategy, 2002-14 8
Figure 4: 5EU ACE inhibitor* market, 2008 and 2014 10
Figure 5: Servier prescription pharmaceutical sales, generic and branded ($m), 2002-14 11
Figure 6: Servier SWOT analysis 13
Figure 7: Key corporate developments 23
Figure 8: Current corporate structure 25
Figure 9: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 27
Figure 10: Key product sales ($m), 2002-14 29
Figure 11: Servier key sales growth drivers and resistors ($m), 2002-08 31
Figure 12: Servier key sales growth drivers and resistors ($m), 2008-14 34
Figure 13: Servier prescription pharmaceutical sales by therapy area ($m), 2002-14 36
Figure 14: Servier prescription pharmaceutical sales by geographic region ($m), 2002-14 39
Figure 15: Servier launch/core/expiry configuration ($m), 2008-14 47
Figure 16: Servier prescription pharmaceutical sales by molecule type ($m), 2002-14 48
Figure 17: Servier prescription pharmaceutical sales by source ($m), 2002-14 50

[Inhaltsverzeichnis ausblenden]

List of Tables
Table 1: Servier - PharmaVitae forecasts at a glance 7
Table 2: Servier key product developments, 2009 19
Table 3: Servier product deals and alliances, 2009 19
Table 4: Servier technology deals and alliances, 2009 20
Table 5: Servier company announcements, 2009 21
Table 6: Servier product portfolio overview ($m), 2002-08 30
Table 7: Servier product portfolio overview ($m), 2008-14 33
Table 8: Servier prescription pharmaceutical sales by therapy area ($m), 2008-14 37
Table 9: Servier prescription pharmaceutical sales by geographic region ($m), 2008-14 40
Table 10: Servier launch portfolio overview ($m), 2008-14 42
Table 11: Servier core portfolio overview ($m), 2008-14 43
Table 12: Servier expiry portfolio overview ($m), 2008-14 45
Table 13: Servier generics portfolio overview ($m), 2008-14 46
Table 14: Servier prescription pharmaceutical sales by molecule type ($m), 2008-14 49
Table 15: Servier prescription pharmaceutical sales by source ($m), 2008-14 51
Table 16: Total Servier sales by business unit ($m), 2002-08 54
Table 17: Key products overview 56
Table 18: Preterax: overview 57
Table 19: Preterax: sales forecast ($m), 2008-14 58
Table 20: Coversyl: overview 60
Table 21: Coversyl: sales forecast ($m), 2008-14 61
Table 22: Vastarel: overview 63
Table 23: Vastarel: sales forecast ($m), 2008-14 64
Table 24: Daflon: overview 65
Table 25: Daflon: sales forecast ($m), 2008-14e 66
Table 26: Natrilix: overview 67
Table 27: Natrilix: sales forecast ($m), 2008-14 68
Table 28: Procoralan: overview 69
Table 29: Procoralan: sales forecast ($m), 2008-14 70
Table 30: Diamicron: overview 72
Table 31: Diamicron: sales forecast ($m), 2008-14 73
Table 32: Protelos: overview 75
Table 33: Protelos: sales forecast ($m), 2008-14 76
Table 34: Valdoxan: overview 78
Table 35: Valdoxan: sales forecast ($m), 2008-14 79
Table 36: Servier's R&D pipeline (Phase I-registration) 81
Table 37: Exchange rates, 2009 83

List of Figures
Figure 1: The PharmaVitae Explorer 3
Figure 2: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6
Figure 3: Servier focus strategy, 2002-14 8
Figure 4: 5EU ACE inhibitor* market, 2008 and 2014 10
Figure 5: Servier prescription pharmaceutical sales, generic and branded ($m), 2002-14 11
Figure 6: Servier SWOT analysis 13
Figure 7: Key corporate developments 23
Figure 8: Current corporate structure 25
Figure 9: Servier prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 27
Figure 10: Key product sales ($m), 2002-14 29
Figure 11: Servier key sales growth drivers and resistors ($m), 2002-08 31
Figure 12: Servier key sales growth drivers and resistors ($m), 2008-14 34
Figure 13: Servier prescription pharmaceutical sales by therapy area ($m), 2002-14 36
Figure 14: Servier prescription pharmaceutical sales by geographic region ($m), 2002-14 39
Figure 15: Servier launch/core/expiry configuration ($m), 2008-14 47
Figure 16: Servier prescription pharmaceutical sales by molecule type ($m), 2002-14 48
Figure 17: Servier prescription pharmaceutical sales by source ($m), 2002-14 50
[Tabellenverzeichnis ausblenden]